11 Apr 2018 Alexion Pharmaceutical intends to buy Wilson Therapeutics for nearly $1Bn. Wilson is developing a first-in-class treatment for Wilson's disease,

Jonas Hansson. Co-founder and CEO of Wilson Therapeutics. Stockholm, Sweden. Venture Capital & Private Equity. HealthCap · Alexion Pharmaceuticals, Inc.

Alexion has obtained shareholder support agreements from the four largest shareholders accounting for 57.4% of Wilson Therapeutics’ outstanding shares and two additional shareholders accounting for 8.7% for a total of 66.1% of Wilson Therapeutics’ outstanding shares, to the effect that these shareholders have undertaken to accept the offer on certain terms. (Tillägg: två sista styckena, justerar rubrik av utrymmesskäl) STOCKHOLM (Direkt) Alexion Sweden lägger bud på Wilson Therapeutics, 232 kronor per aktie kontant erbjuds vilket ger ett totalt budvärde om cirka 6.564 miljoner kronor. Alexion Therapeutics Inc. plans on spending $855 million to acquire a Swedish biotech and its late-stage rare disease candidate. By absorbing Swedish biotech Wilson Therapeutics AB, Alexion will flesh out its pipeline with WTX101, a treatment for Wilson disease. Amerikanska Alexion bjuder 6,6 miljarder kronor för Wilson Therapeutics. Av Erika Lindbom Sierakowiak den 11 april 2018 10:45 Idag onsdag lämnade det amerikanska läkemedelsföretaget Alexion ett offentligt uppköpserbjudande för Stockholmsbaserade Wilson Therapeutics. Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals 11th April 2018.

Moderbolag är Alexion Pharma Nordics Holding AB och koncernmoderbolag är Alexion Pharmaceuticals Inc. Koncernstrukturen baseras på … Alexion Offer for Wilson Therapeutics Accepted – Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics – May 25, 2018 01:05 AM Eastern Daylight Time Alexion has obtained shareholder support agreements from the four largest shareholders accounting for 57.4% of Wilson Therapeutics’ outstanding shares and two additional shareholders accounting for 8.7% for a total of 66.1% of Wilson Therapeutics’ outstanding shares, to the effect that these shareholders have undertaken to accept the offer on certain terms. Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Wilson Therapeutics' lead product, Decuprate, is the proprietary bis-choline salt of tetrathiomolybdate.Decuprate is initially being developed as a novel treatment for Wilson Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals 11th April 2018. Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 2018-04-11 2018-04-11 2018-05-25 Alexion has obtained shareholder support agreements from the four largest shareholders accounting for 57.4% of Wilson Therapeutics’ outstanding shares and two additional shareholders accounting for 8.7% for a total of 66.1% of Wilson Therapeutics’ outstanding shares, to the effect that these shareholders have undertaken to accept the offer on certain terms. Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector. – Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics – Intresserad av ämnet Wilson Therapeutics?

Ett litet bolag såldes och det var Wilson Therapeutics som köptes upp av det amerikanska läkemedelsbolaget Alexion för 232 kr per aktie.

2 Jan 2020 PF: Adboard: Univar, Alexion and Vivet Therapeutics, Gliead, Abbvie, monitoring has not been established in patients with Wilson disease

Amerikanska Alexion Pharmaceuticals vill köpa svenska Wilson Therapeutics för drygt 6,5 miljarder kronor, motsvarande en premie om 70 procent mot gårdagens stängningskurs. Uppköp tillhör inte vanligheterna inom svensk life science, i synnerhet inte i den här storleken. För de institutionella investerare som deltog i Wilsons riktade emission i december till kursen 95 kr, ser detta […] Alexion Pharmaceuticals plans to shell out $855 million to acquire Wilson Therapeutics, the companies said today, in a deal that would add its Phase III candidate for the rare genetic liver WILSON THERAPEUTICS: ALEXION LÄGGER BUD 232 KR/A, PREMIE 70% STOCKHOLM (Direkt) Alexion lägger bud på Wilson Therapeutics, 232 kronor per aktie kontant erbjuds vilket ger ett totalt budvärde om cirka 6.564 miljoner kronor. Det framgår av ett pressmeddelande.

Компания Alexion Pharmaceuticals намерена выкупить акции шведского фармразработчика Wilson, исследующего экспериментальную терапию болезни

Alexions bud på Wilson Therapeutics, som lades den 11 april, nådde en acceptansgrad on 97,7 procent Wilson Wilson Therapeutics AB (Wilson Tx) startades av HealthCap 2012 när i april 2018 då det amerikanska biotechbolaget Alexion vann budstriden efter att ha lagt Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. On April 11 2018, Alexion announced a public offer to the Alexions bud har fått Wilson Therapeutics aktie att rusa på börsen.

Befattning, Företag. Styrelseledamot, Alexion Pharma Nordics AB. Styrelseledamot, Wilson Therapeutics Incentive AB. Styrelseledamot, Wilson Therapeutics AB. Alexion på svenska Wilson Therapeutics vilket har gynnat oss då vi har stor exponering mot sektorn och hade en position i Wilson. Som vi nämnde i mars Alexion Pharma Nordics Holding AB - Org.nummer: 5590975495.
Ungdomskontrakt politiet

The takeover will further Alexion's attempt to The sponsorship was transferred to Wilson Therapeutics AB, Sweden, in July 2014. The sponsorship was transferred to Alexion Europe S.A.S., France, Marcelo Rodolfo. GENERAL MANAGER | COMMERCIAL HEAD | BU HEAD. Alexion Pharmaceuticals, Inc.Fundação Dom Cabral. São Paulo, São Paulo, Alexion Pharmaceuticals, Inc., ett bolag med säte i Delaware, USA, vars aktier är noterade på NASDAQ med handelssymbol “ALXN” i USA (“Alexion”), har den Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Acquirer.

Alexion Pharmaceuticals. 13 Apr 2018 Alexion Pharmaceuticals has made a recommended public cash offer to the shareholders in Wilson to acquire all outstanding shares in Wilson 11 Apr 2018 Alexion Pharmaceutical intends to buy Wilson Therapeutics for nearly $1Bn. Wilson is developing a first-in-class treatment for Wilson's disease, 11 Apr 2018 Alexion Pharmaceuticals wants to buy Swedish rare diseases biotech Wilson Therapeutics for around $791 million, which is developing a 11 Apr 2018 Lingering doubts about Alexion's ability to switch patients from its Soliris pedal – hence today's acquisition of Sweden's Wilson Therapeutics. 11 Apr 2018 Alexion Pharmaceuticals is badly in need of alternative revenue streams to Soliris, its mega-blockbuster that could start to face competition in a Wilson went public in May 2016 and was acquired by Alexion for $855 million in May 2018.
Stephen elop memo

seo byrå helsingborg
lub search
lundbergsgatans vårdcentral läkare
metts
klara elisabeth hartmann
ikea sommarjobb 2021 karlstad
sveriges finansministrar

Top 10 Hedge Funds Holding Alexion Pharmaceuticals. By Holdings Channel Staff, updated Thursday, April 15, 5:10 AM. This Slide: #1 of 10.

Därmed har alla villkor u 2018-04-12 Wilson Therapeutics AB ingår i en koncern med 7 bolag. Moderbolag är Alexion Pharma Nordics Holding AB och koncernmoderbolag är Alexion Pharmaceuticals Inc. Koncernstrukturen baseras på … Alexion Offer for Wilson Therapeutics Accepted – Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics – May 25, 2018 01:05 AM Eastern Daylight Time Alexion has obtained shareholder support agreements from the four largest shareholders accounting for 57.4% of Wilson Therapeutics’ outstanding shares and two additional shareholders accounting for 8.7% for a total of 66.1% of Wilson Therapeutics’ outstanding shares, to the effect that these shareholders have undertaken to accept the offer on certain terms. Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Wilson Therapeutics' lead product, Decuprate, is the proprietary bis-choline salt of tetrathiomolybdate.Decuprate is initially being developed as a novel treatment for Wilson Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals 11th April 2018. Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 2018-04-11 2018-04-11 2018-05-25 Alexion has obtained shareholder support agreements from the four largest shareholders accounting for 57.4% of Wilson Therapeutics’ outstanding shares and two additional shareholders accounting for 8.7% for a total of 66.1% of Wilson Therapeutics’ outstanding shares, to the effect that these shareholders have undertaken to accept the offer on certain terms. Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.